Search

Corcept Therapeutics Inc

Открыт

СекторЗдравоохранение

123.37 0.77

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

121.51

Макс.

125.97

Ключевые показатели

By Trading Economics

Доход

75M

43M

Продажи

91M

256M

P/E

Средняя по отрасли

254.717

57.371

Прибыль на акцию

0.36

Рентабельность продаж

16.782

Сотрудники

730

EBITDA

91M

47M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+14.41% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.9B

13B

Предыдущая цена открытия

122.6

Предыдущая цена закрытия

123.37

Новостные настроения

By Acuity

59%

41%

292 / 340 Рейтинг в Healthcare

Corcept Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 авг. 2026 г., 19:36 UTC

News

Corcept Therapeutics shares are lower despite Zacks raising Q3 2026 EPS estimate to $0.34. The company reported Q2 earnings of $0.36 per share.

21 авг. 2026 г., 20:01 UTC

News

Corcept Therapeutics Inc is higher today, supported by strong sector performance and increased trading volume amid a positive growth outlook and upcoming FDA decision on Relacorilant.

20 авг. 2026 г., 23:41 UTC

Corcept Therapeutics Inc. shares are trading roughly flat in after-market hours. The asset remains above its 20-day moving average.

13 авг. 2026 г., 19:46 UTC

Corcept Therapeutics Inc is declining today, with no specific news identified. The stock peaked earlier but has since retraced from that high.

12 авг. 2026 г., 19:16 UTC

Corcept Therapeutics Inc shares are higher today amid a positive trend in U.S. stocks, despite geopolitical tensions and rising crude oil prices.

11 авг. 2026 г., 20:06 UTC

Corcept Therapeutics Inc. shares are lower today, having declined steadily after reaching a session high earlier. The stock remains above its 20-day moving average.

10 авг. 2026 г., 19:16 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early drop despite a broader market decline amid labor market concerns.

7 авг. 2026 г., 21:01 UTC

Corcept Therapeutics Inc shares are lower in after-market trading, declining despite being above its 20-day moving average and near the upper end of its one-month range.

5 авг. 2026 г., 19:56 UTC

Corcept Therapeutics Inc's shares are higher today, reflecting a generally positive market environment. The stock remains significantly above its 20-day moving average.

4 авг. 2026 г., 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3 авг. 2026 г., 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31 июл. 2026 г., 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30 июл. 2026 г., 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29 июл. 2026 г., 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28 июл. 2026 г., 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27 июл. 2026 г., 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

24 июл. 2026 г., 21:01 UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

22 июл. 2026 г., 19:51 UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

21 июл. 2026 г., 17:06 UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

20 июл. 2026 г., 18:13 UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Сравнение c конкурентами

Изменение цены

Corcept Therapeutics Inc Прогноз

Целевая цена

By TipRanks

14.41% рост

Прогноз на 12 месяцев

Средняя 141 USD  14.41%

Максимум 165 USD

Минимум 50 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Corcept Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

5 ratings

4

Покупка

0

Удержание

1

Продажа

Настроения

By Acuity

292 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat